New York, Kicking off the season for pharmaceutical professionals to come together digitally (09-27 May, 2022) as well as in-person (17-19 May, 2022). CPHI North America will be held as a SMART event, with three weeks of dedicated pharma learning and partnering.
The benefit for the CPHI pharma community, which relies on a widening global supply chain, is that a SMART event format stimulates greater collaboration within the industry. Buyers and sellers are able to actively research new partners ahead of attendance, before hosting meetings digitally or in-person at the event – which will be held at the Pennsylvania Convention Center.
Adam Andersen, Executive Vice President, Pharma at Informa Markets, commented: “Everything we do at CPHI is to facilitate industry partnering and it’s in these vital face to face interactions that conversations take on greater depth and deals are signed that will deliver pharma’s future growth.”
Pharma professionals will be further empowered by the return of a full conference program spanning four tracks: ‘US market insights’, ‘drug manufacturing dynamics’, ‘navigating supply chain and capacity challenges’, and ‘biologics and bioprocessing’. Amongst a multitude of detailed insights and analysis, sessions will explore the impacts in North America of ‘continuous manufacturing adoption’, ‘reshoring’, ‘ESG initiatives’, ‘Covid therapeutics’ and the implications for innovators of the ‘novel excipients pilot program’. The event also features a dedicated bioprocessing track launched in collaboration with the Jefferson Institute of Bioprocessing and a special, NSF International training course (additional fee applies) on ‘corrective and preventive actions (CAPAs) based on the identified root cause’.
Ahead of North America’s only end-to-end pharma event, newly released CPHI findings show a remarkable 65% of US companies are predicting growth in excess of 20% in 2022 – with CDMOs (Contract Development and Manufacturing Organisations)reporting the most explosive rates.
Emphasizing the timely significance of the conference’s ‘capacity track’ and, in a further positive for attendees, nearly half (45%) of US based companies said they expected ‘a capacity crunch at CDMOs in the next year due to surging approvals’.
In fact, two thirds of respondents believe this surging growth will cause the emergence of a two-tier market, in which large and medium pharma align with strategic partners, while smaller biotechs may potentially struggle to find appropriate outsourcing partners.
Andersen added: “Pharma companies in North America are predicting high levels of growth in 2022, particularly manufacturers and CDMOs. This is driven by new drug products entering the market, the success of recent approvals, and macro changes in the location of manufacturing. Underpinning this is a widening and diversifying pharma supply chain – which is why CPHI North America has such an important role to play in enabling the industry to source, connect and learn.”
Registration is free to all until April 10th and, highlighting the importance of the event to buying and partnering, 48% of CPHI North America attendees are C-suite level, with 65% having purchasing responsibility – meaning it is an opportunity few companies can afford to miss.
CPHI North America spans the entire pharma supply chain from ingredients, finished dose, contract services and fine chemicals to biologics, packaging, and machinery, with seven collocated events, for more information please visit: www.CPHI.com/northamerica/en